Advertisement

The Use of Novel Oral Anticoagulants in Adult Congenital Heart Disease: A Single Center Experience

Published:November 11, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.11.002
      We read the study by Niesert et al in a recent edition of the American Journal of Cardiology. The investigators present the first clinical evidence on the use of novel oral anticoagulants (NOACs) in adult congenital heart disease (ACHD). In their study, 55 patients with congenital heart disease were started on NOACs. Median follow-up was 6 months and during this period only one NOAC therapy was stopped as a result of bleeding.
      • Niesert A.C.
      • Pujol C.
      • Engelhardt A.
      • Lummert E.
      • Schön P.
      • Braun S.
      • Ewert P.
      • Kaemmerer H.
      OP-047 initial experience on the use of novel oral anticoagulants (NOAC) in adults with congenital heart disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Niesert A.C.
        • Pujol C.
        • Engelhardt A.
        • Lummert E.
        • Schön P.
        • Braun S.
        • Ewert P.
        • Kaemmerer H.
        OP-047 initial experience on the use of novel oral anticoagulants (NOAC) in adults with congenital heart disease.
        Am J Cardiol. 2015; 115: S21
        • Bouchardy J.
        • Therrien J.
        • Pilote L.
        • Ionescu-Ittu R.
        • Martucci G.
        • Bottega N.
        • Marelli A.J.
        Atrial arrhythmias in adults with congenital heart disease.
        Circulation. 2009; 120: 1679-1686
        • Jensen A.S.
        • Idorn L.
        • Nørager B.
        • Vejlstrup N.
        • Sondergaard L.
        Anticoagulation in adults with congenital heart disease: the who, the when and the how?.
        Heart. 2015; 101: 424-429
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • Eikelboom J.
        • Oldgren J.
        • Parekh A.
        • Pogue J.
        • Reilly P.A.
        • Themeles E.
        • Varrone J.
        • Wang S.
        • Alings M.
        • Xavier D.
        • Zhu J.
        • Diaz R.
        • Lewis B.S.
        • Darius H.
        • Diener H.C.
        • Joyner C.D.
        • Wallentin L.
        • RE-LY Steering Committee and Investigators
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Anderson J.L.
        • Halperin J.L.
        • Albert N.M.
        • Bozkurt B.
        • Brindis R.G.
        • Curtis L.H.
        • DeMets D.
        • Guyton R.A.
        • Hochman J.S.
        • Kovacs R.J.
        • Ohman E.M.
        • Pressler S.J.
        • Sellke F.W.
        • Shen W.K.
        • Wann L.S.
        • Curtis A.B.
        • Ellenbogen K.A.
        • Estes 3rd, N.A.
        • Ezekowitz M.D.
        • Jackman W.M.
        • January C.T.
        • Lowe J.E.
        • Page R.L.
        • Slotwiner D.J.
        • Stevenson W.G.
        • Tracy C.M.
        • Fuster V.
        • Rydén L.E.
        • Cannom D.S.
        • Crijns H.J.
        • Curtis A.B.
        • Ellenbogen K.A.
        • Le Heuzey J.Y.
        • Kay G.N.
        • Olsson S.B.
        • Prystowsky E.N.
        • Tamargo J.L.
        • Wann S.
        Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 61: 1935-1944
        • Skanes A.C.
        • Healey J.S.
        • Cairns J.A.
        • Dorian P.
        • Gillis A.M.
        • McMurtry M.S.
        • Mitchell L.B.
        • Verma A.
        • Nattel S.
        • Cardiovascular Society Atrial Fibrillation Guidelines Committee
        Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
        Can J Cardiol. 2012; 28: 125-136
        • Khairy P.
        • Van Hare G.F.
        • Balaji S.
        • Berul C.I.
        • Cecchin F.
        • Cohen M.I.
        • Daniels C.J.
        • Deal B.J.
        • Dearani J.A.
        • Nd Groot
        • Dubin A.M.
        • Harris L.
        • Janousek J.
        • Kanter R.J.
        • Karpawich P.P.
        • Perry J.C.
        • Seslar S.P.
        • Shah M.J.
        • Silka M.J.
        • Triedman J.K.
        • Walsh E.P.
        • Warnes C.A.
        PACES/HRS expert consensus statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD).
        Heart rhythm. 2014; 11: e102-e165
      1. Report of the Fifth European Meeting on Adult Congenital Heart Disease, 10–11 April 2014, Amsterdam, Netherlands. Available at: http://www.escardio.org/The-ESC/Communities/Working-Groups/Working-Group-on-Grown–up-Congenital-Heart-Disease/Education/Report-of-the-Fifth-European-meeting-on-Adult-Congenital-Heart-Disease-10-11-Ap. Accessed on November 1, 2015.

      2. NOTE registry. Available at: http://www.isachd.org/content/note-registry. Accessed on November 1, 2015.

      Linked Article